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DObjective: Although implicitly accepted by many that the durability of valve-sparing aortic root replacement in
patients with bicuspid aortic valve disease and connective tissue disorders will be inferior, this hypothesis has not
been rigorously investigated.
Methods: From 1993 to 2009, 233 patients (27% bicuspid aortic valve, 40% Marfan syndrome) underwent
Tirone David valve-sparing aortic root replacement. Follow-up averaged 4.7  3.3 years (1102 patient-
years). Freedom from adverse outcomes was determined using log-rank calculations.
Results: Survival at 5 and 10 years was 98.7%  0.7% and 93.5%  5.1%, respectively. Freedom from reop-
eration (all causes) on the aortic root was 92.2%  3.6% at 10 years; 3 reoperations were aortic valve replace-
ment owing to structural valve deterioration. Freedom from structural valve deterioration at 10 years was 96.1%
 2.1%. No significant differences were found in survival (P ¼ .805, P ¼ .793, respectively), reoperation
(P¼ .179, P¼ .973, respectively), structural valve deterioration (P¼ .639, P¼ .982, respectively), or any other
functional or clinical endpoints when patients were stratified by valve type (tricuspid aortic valve vs bicuspid
aortic valve) or associated connective tissue disorder. At the latest echocardiographic follow-up (95% com-
plete), 202 patients (94.8%) had none or trace aortic regurgitation, 10 (4.7%) mild, 0 had moderate to severe,
and 1 (0.5%) had severe aortic regurgitation. Freedom from greater than 2þaortic regurgitation at 10 years was
95.3%  2.5%. Six patients sustained acute type B aortic dissection (freedom at 10 years, 90.4%  5.0%).
Conclusions: Tirone David reimplantation valve-sparing aortic root replacement in carefully selected young pa-
tients was associated with excellent clinical and echocardiographic outcome in patients with either a tricuspid
aortic valve or bicuspid aortic valve. No demonstrable adverse influence was found for Marfan syndrome or con-
nective tissue disorder on durability, clinical outcome, or echocardiographic results. (J Thorac Cardiovasc Surg
2013;145:117-27)Supplemental material is available online.
The surgical management of aortic valve regurgitation and
aortic root pathology has evolved during the past 3 de-
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The Journal of Thoracic and Caimportant—but different—inherent limitations (eg, indefi-
nite need for anticoagulation versus limited durability, re-
spectively). Based on the premise that preserving the
patient’s native aortic valve would be associated with a sub-
stantially lower incidence of all valve-related complica-
tions, several surgical techniques have been described and
are generically termed ‘‘valve-sparing aortic root replace-
ment’’ (V-SARR).2,3
V-SARR has been proposed as a reasonable treatment al-
ternative for patients with connective tissue disorders
(CTDs) such as Marfan syndrome (MFS) and bicuspid aor-
tic valve (BAV) disease. However, several groups have ob-
served high reoperation rates in both patients with MFS and
BAV and raised concern about the use of V-SARR in such
patients.4-8 Thus, the widespread use of V-SARR in
patients with BAV or CTD remains controversial,
especially when a reproducible and durable alternative
exists such as CVG with a mechanical valve.9,10
Furthermore, the reoperation risks remain undetermined
whether reoperation after V-SARR should become
necessary, but the reoperation mortality rate after otherrdiovascular Surgery c Volume 145, Number 1 117
Abbreviations and Acronyms
BAV ¼ bicuspid aortic valve
CTD ¼ connective tissue disorder
CVG ¼ composite valve graft
MFS ¼ Marfan syndrome
V-SARR ¼ valve-sparing aortic root replacement
TAV ¼ tricuspid aortic valve
TTE ¼ transthoracic echocardiogram
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Dtypes of aortic root replacement procedures has been
reported to exceed 11%.11
Hence, we compared the midterm survival, risk of reop-
eration, incidence of structural valve deterioration, and de-
gree of residual aortic regurgitation (AR) in patients with
either a tricuspid aortic valve (TAV) or BAVwith or without
CTD using the Tirone David reimplantation technique of
V-SARR.METHODS
Patients
ATirone David-I, Tirone David-V, or Tirone David-V-Stanford modifi-
cation V-SARR was performed in 233 patients at Stanford from July 1993
to December 2009 (total number at Stanford now>300) with the follow-up
window closing in June 2010. One patient undergoing root repeat replace-
ment after a previous Yacoub remodeling procedure for acute aortic dissec-
tion was excluded. A total of 170 patients (73%) had a TAVand 63 (27%)
a BAV. The mean age was 36  13 years (range, 11-68) for the TAV group
and 43  12 years (range, 19-64) for the BAV group; 115 (67%) and 50
(80%) were male patients in the TAVand BAV groups, respectively. No pa-
tient required an emergency procedure for acute type A aortic dissection.
Additional demographic variables according to valve type are listed in
Table 1. The distribution of patients by valve type over time is illustrated
in Figure 1, A. The age distribution of the TAV and BAV patients and
BAV subtypes according to Sievers’ classification12 are shown in
Figure 1, B and C, respectively. The patients in the TAV group were signif-
icantly younger, taller, and slimmer than in the BAV group (Table 1). While
the TAV group had larger aortic root dimensions, the BAV group had larger
ascending aortic diameters.
Operative Procedure
Early in the experience, the original V-SARR reimplantation technique
described by David and Feindel (Tirone David-I) was used in 26 patients.3
Thereafter, 19 patients received a Tirone David-V procedure. The Tirone
David-V-Stanford modification V-SARR technique has been used exclu-
sively since December 2002 in 188 patients.13
Total or partial transverse arch replacement was performed when neces-
sary using the ‘‘Peninsula technique,’’ with a single sigmoid-shaped suture
line from the ligamentum to the innominate artery using selective ante-
grade cerebral perfusion (usually a 6-8 mm arterial perfusion graft sewn
to the innominate artery; a distribution of cannulation sites is given in
Table 2) and moderate hypothermic circulatory arrest (bladder 25C-
27C).14 Concomitant arch replacement was performed more frequently
in patients with a BAV because their aneurysmal pathologic features often
included the arch15 (Figure 1, D).
Coronary artery reimplantation as full-thickness Carrel ‘‘button’’ anas-
tomoses was done whenever possible. One patient with an anomalous, in-
tramural coronary artery had his left main coronary artery reconstructed
using an arterial (superficial femoral) autograft. Six patients required118 The Journal of Thoracic and Cardiovascular Surga Kay-Zubiate right coronary reconstruction (2-3–cm greater saphenous
vein interposition graft) because of technical complications. The distribu-
tion and type of aortic valve repairs used in the TAV and BAV group and
concomitant procedures are listed in Table 2.
Valve Repair
Aortic valve cusp repair was performed in 63 of the TAV patients
(37%). Cusp repair consisted of shortening the free margin at the nodulus
of Arantius in all 63 TAV patients without formal cusp plication sutures.
Among the BAV patients, 42 required cusp-free margin shortening
(67%) using 1 or more sutures to correct prolapse and cusp redundancy.
A total of 68 sutures were placed, resulting in an average of about 1.4 su-
tures (range, 1-4) per patient. Seven of these sutures were centrally placed
at the nodulus of Arantius, and the remaining 61 sutures were placed further
toward the commissures along the cusp-free margin. In addition, a small
triangular resection of the raphe was performed in 7 BAV patients, along
with cusp-free margin shortening. Creation of commissural neosuspensory
cords using 5-0 Gore-Tex sutures was done in 3 BAV patients to replace
ruptured ‘‘truncal’’ commissural suspensory chords.
Endpoints
The primary endpoints were all-cause overall mortality; reoperation on
the aortic root for any cause; structural valve deterioration (SVD); and free-
dom from greater than 2þAR.
Follow-up
Postoperative valve-related adverse events were compiled and analyzed
according to the American Association for Thoracic Surgery–Society of
Thoracic Surgeons–European Association Cardio-Thoracic Surgery
Guidelines for Reporting Morbidity and Mortality after Cardiac Valvular
Operations.16 The patients were followed up clinically on a regular basis;
current follow-up data were obtained by interviewing the patients and their
physicians by telephone. The mean standard deviation follow-up was 4.7
 3.3 years; the maximum follow-up was 15.1 years (median, 4.2 years;
interquartile range, 2.3-6.6 years; cumulative, 1102 patient-years). At 5
years of follow-up, 88 patients remained at risk, but only 18 patients
were at risk at 10 years; for those with MFS or other CTD, the correspond-
ing numbers were 46 and 7. SVD was categorized according to the valve-
reporting guidelines.16
Echocardiography
Transthoracic echocardiograms (TTEs) were performed periodically
(usually once annually) postoperatively. We obtained late TTE images in
213 of 224 patients (233 minus 4 deaths and 5 who underwent late
AVR), equating to 95% late echocardiographic follow-up completeness.
The average period of late TTE was 3.9  3.3 years postoperatively (me-
dian, 3.4 years; interquartile range, 1.24-5.8 years; maximum, 13.4 years).
AR was graded as either none or trivial (grade 0), mild (grade 1þ), mod-
erate (grade 2þ), moderate to severe (grade 3þ), severe (grade 4þ) according
to color flow mapping and continuous wave and pulsed wave Doppler by 2
expert echocardiographers (D.H.L. and A.-S.B.), who specifically focused
on the vena contracta width and AR timing and mechanism.
Statistical Analysis
Continuous variables are expressed as the mean  1 standard deviation
or median and interquartile range. The Mann-Whitney rank sum test was
used to compare the 2-group continuous variables. Categorical data were
tabulated in 23n tables, and 2-group comparisons were made using the
chi-square test or Fisher’s exact probability test. The Kaplan-Meier method
was used to calculate the nonadjusted actuarial survival and freedom from
adverse events; a statistical comparison of event rates was determined us-
ing log-rank calculations. For perspective, age-, gender-, and race-matched
survival estimates for the US population were calculated. To identify theery c January 2013
TABLE 1. Baseline clinical patient characteristics
Characteristic
TAV
(n ¼ 170)
BAV
(n ¼ 63)
P
value
Age (y)
Mean  SD 36  13 43  12 <.001
Range 11-68 19-64
Male gender 115 (67) 50 (80) .08
Height (cm)
Mean  SD 184  12 175  24 .003
Range 148-214 155-198
Weight (kg)
Mean  SD 81  19 84  19 .002
Range 30-152 42-127
BMI (kg/m2)
Mean  SD 24  5 26  16 <.001
Range 11-48 13-45
BSA (m2)
Mean  SD 2.0  0.3 2.0  0.3 .798
Range 1.1-2.7 1.4-2.6
Hypertension 44 (26) 23 (37)
Diabetes (oral treatment or insulin) 4 (2) 2 (3)
Marfan syndrome 91 (54) 3 (5) <.001
Loeys-Dietz syndrome 8 (5) 0
Acute aortic dissection 0 0
Sinus rhythm 170 (100) 63 (100)
LVEF (%)
Median 61 62 .1
IQR 57-65 60-65
Aortic root diameter (cm)
Median 5.0 4.3 <.001
IQR 4.6-5.4 3.9-4.8
Aortic ascending diameter (cm)
Median 3.8 4.9 <.001
IQR 3.0-4.8 4.4-5.3
Aortic regurgitation
None/trivial 66 23
Mild 43 21
Moderate to severe 43 9
Severe 18 10
Average 1.9  1.3 1.7  1.5
Previous cardiovascular surgery 8 (5) 4 (6)
Data presented as mean standard deviation, median and IQR, or n (%). BAV, Bicus-
pid aortic valve; BMI, body mass index; BSA, body surface area; EF, ejection fraction;
IQR, interquartile range; NYHA, New York Heart Association; TAV, tricuspid aortic
valve.
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ard models. Commercially available statistics and graphing packages, Sig-
maPlot and SigmaStat, version 11.0 (Systat Software, San Jose, Calif) were
used for descriptive and analytical statistical procedures. A probability
value of less than .05 was considered statistically significant. The Stanford
institutional review board approved the present study, and informed con-
sent was obtained from the patients at the time of contact.
RESULTS
Survival
The in-hospital (30-day) mortality rate was 0.9%
(2/233). One death was from complications arising from re-
implantation of a small, nondominant right coronary arteryThe Journal of Thoracic and Cawith subsequent right ventricular failure. The second death
was from cerebral infarction in a patient with a chronic aor-
tic dissection. Early (30-day) morbidity is summarized in
Table E1 and late complications in Table E2.
Two late deaths occurred. One patient committed suicide
6 weeks postoperatively and one patient with MFS died of
cardiomyopathy 10 years postoperatively. The actuarial sur-
vival estimate at 5 and 10 years was 98.7%  0.7% and
93.5%  5.1%, respectively (Figure 2, A).
Survival after V-SARR was not significantly different
than that of the general US population, matched for age,
gender, and race (Figure 2, B). No significant difference
was seen in mid-term survival after V-SARR between the
TAVand BAV subsets (P¼ .805); however, caution in inter-
preting this finding is necessary because the cumulative
follow-up was much shorter in the BAV subset (TAV, 886
years; BAV, 216 years; Figure 2, C). Similarly, no statisti-
cally significant difference was seen in survival between
those patients with a diagnosis of CTD and the rest of the
population (P ¼ .793, Figure 2, D).
Reoperation
A total of 6 patients required reoperation on the aortic
root for any cause. The freedom from reoperation at 5 and
10 years was 98.0%  1.2% and 92.2%  3.6%, respec-
tively (Figure 3, A). No demonstrable difference was seen
in reoperation between the TAV and BAV subsets
(P¼ .179; Figure 3, B) or between those with MFS or other
CTDs and the rest of the patients (P ¼ .973; Figure 3, C).
One young patient with MFS required mitral valve replace-
ment because of progressive mitral regurgitation 6 years
after V-SARR; he requested replacement of his well-
functioning native aortic valve at that time to avoid a poten-
tial third reoperation because he opted for a mechanical
mitral valve.
Endocarditis
Two patients developed endocarditis; both had an un-
complicated early postoperative course. Neither had a posi-
tive blood culture at reoperation, but both had been treated
with antibiotics previously for nonspecific symptoms. One
infected BAV patient underwent AVR with a homograft 1
year postoperatively. The second patient with TAV had a lo-
calized infection near the right coronary artery reimplanta-
tion site; local resection and debridement were performed
successfully.
Late Aortic Dissection
Six patients developed acute Stanford type B aortic dis-
section 19 to 103 months postoperatively, a serious prob-
lem. Five were female patients, and all had an underlying
CTD (5 with MFS and 1 with Loeys-Dietz syndrome;
Table E3). None had undergone concomitant arch replace-
ment. All patients were treated conservatively and, tordiovascular Surgery c Volume 145, Number 1 119
FIGURE 1. A, Distribution of patients undergoing valve-sparing aortic root replacement according to type of aortic valve. B, Age distribution of patients
with tricuspid (TAV) and bicuspid aortic valve (BAV). C, Distribution of patients (n,%) with a BAVaccording to Sievers’ classification. D, Distribution of
arch replacement during study period according to valve type.
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Stanford type B aortic dissection at 5 and 10 years was
97.5%  1.2% and 90.4%  5.0%, respectively
(Figure E1, A). A significant difference was seen in the free-
dom from acute Stanford type B dissection between those
with MFS or other CTD and the rest of the patients
(P ¼ .01, Figure E1, B).Aortic Valve Function
At 5 and 10 years, the freedom from SVD was 97.6% 
1.4% and 96.1%  2.1%, respectively (Figure E2, A). No
significant difference was found in SVD between the TAV
and BAV subsets (P ¼ .639; Figure E2, B) nor between
the patients with or without MFS or other CTDs
(P ¼ .982; Figure E2, C). The characteristics of the 3 pa-
tients who required late AVR because of SVD are summa-
rized in Table E4 (note, 1 patient with severe AR when
the present study was closed [listed as SVD according to120 The Journal of Thoracic and Cardiovascular Surgthe guidelines] subsequently underwent AVR). The 4 pa-
tients who developed SVD during follow-up had either no
or mild AR on the first postoperative echocardiogram. A
significant difference was seen in the freedom from SVD
and reoperation, however, between those patients with 4þ
AR preoperatively and the rest of the patients (P< .001,
Figure E3, A and B).
Based on the latest TTE, 202 patients (94.8%) had either
no or trace AR, 10 (4.7%) had mild AR, 0 had moderate to
severe AR, and 1 (0.5%) had severe AR (who subsequently
underwent AVR). Freedom from more than 2þAR at 5 and
10 years was 97.4%  1.5% and 95.3%  2.5%, respec-
tively (Figure E1, C). Only 4 patients developed more
than 2þAR during follow-up.Predictors of Adverse Events
For the Cox regression analysis, we constructed a com-
posite endpoint, but only 14 adverse events occurredery c January 2013
TABLE 2. Intraoperative data for TAV and BAV patients undergoing
Tirone David valve-sparing aortic root replacement
Variable
TAV
(n ¼ 170)
BAV
(n ¼ 63)
P
value
Urgency of surgery (n)
Elective 168 63
Urgent 2 0
Emergent 0 0
Perioperative annular
diameter (cm)
Median 28 27 .238
IQR 25-30 25-30
CPB time (min)
Median 265 309 <.001
IQR 239-301 275-330
Aortic crossclamp time (min)
Median 211 242 <.001
IQR 184-241 212-262
Arch repair 17 (10) 48 (76) <.001
SACP time (min)
Median 25 27 .758
IQR 22-34 23-31
Axillary/innominate 5/14 1/46
Concomitant procedures 39 (23) 6 (10) .02
Mitral valve repair 13 2
PFO 29 2
ASD 6 1
VSD 1 0
CABG 4 2
IABP 4 3
VAD 3 1
Aortic valve cusp repair 63 (37%) 42 (67) <.001
Cusp FM shortening 63 42
Gore-Tex neochords 0 3
Triangular resection 0 7
Data presented as n (%) or median and IQR. ASD, Atrial septal defect; BAV, bicuspid
aortic valve; CABG, coronary artery bypass grafting; CPB, cardiopulmonary bypass;
FM, free margin; IABP, intra-aortic balloon pump; IQR, interquartile range; PFO, pat-
ent foramen ovale; SACP, selective antegrade cerebral perfusion; TAV, tricuspid aortic
valve; VAD, ventricular assist device; VSD, ventricular septal defect.
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[not due to SVD, 2 caused by endocarditis], 1 stroke, and
2 transient ischemic attack). This small number of events
meant the Cox analysis model was unstable, which resulted
in unreliable results without clinical relevance (Table E5).
The extremely wide 95% confidence intervals for the vari-
ables with a significant hazard ratio (age, arch replacement,
AR>2þpreoperatively) are noteworthy.DISCUSSION
In the present retrospective analysis, we observed that
survival after elective Tirone David V-SARR in carefully
selected, relatively young patients is excellent out to 10
years. So far, it is a safe and—most importantly—durable
procedure, irrespective of valve type (TAV or BAV) or the
presence of MFS or another CTD. The one techniqueThe Journal of Thoracic and Caused for root replacement is a strength compared with other
reports.17,18
Different V-SARR Techniques and Modifications of
Original Tirone David Procedure
Of 450 patients undergoing Tirone David-I V-SARR, the
long-term results for 126 patients (20.6%MFS, only 4.0%
BAV, no information provided regarding aortic cusp repair)
who underwent surgery from 1993 to 2000, were recently
reported by Shrestha and colleagues19 from Hannover.
The mean follow-up was 10 2 years; 44 patients remained
at risk at 10 years. The survival estimate was 93%, 85%,
and 70% at 1, 5, and 10 years, respectively. Although lower
than the survival for our patients, any difference was prob-
ably due to differences in the patient substrate (eg, inclusion
of patients with acute type A aortic dissection in the Hann-
over series). It is theoretically plausible, however, that this
difference was due in part to more physiological postoper-
ative aortic root physiology because we used the Tirone
David-V-Stanford modification procedure. The freedom
from AVR was 96%, 91%, and 87% at 1, 5, and 10 years,
respectively.19 MFS was a possible predictor of reoperation
and overall mortality.
David and colleagues20 from Toronto reported the results
for 167 patients (38% MFS, 7% BAV) who underwent
V-SARR. The 10-year survival and freedom from moderate
to severe AR estimate was 92% 3% and 94% 4%, re-
spectively.20 These survival and durability observations par-
alleled our findings.
The high rate of recurrent AR due to annular dilatation,
eventually mandating reoperation, after only 5 years using
the Yacoub remodeling V-SARR procedure21 has convinced
most to abandon its use, especially in patients with MFS.
The Yacoub remodeling procedure (or Tirone David-II or
-III) was used in only 3 other adult patients at Stanford since
1993.
In 2010, De Paulis and colleagues22 reported the results
in 278 patients (15% MFS, 11% BAV, aortic cusp repair
in 9%) from 4 Italian centers using a prefabricated Valsalva
graft for David reimplantation V-SARR. Survival at 10
years and freedom from AR requiring reintervention was
91% and 88%, respectively,22 inferior to the outcomes re-
ported in the present analysis. This commercial Valsalva
graft is popular; our Tirone David-V Stanford modification
technique also creates large billowing neosinuses but is cus-
tomized for each individual patient’s pathologic anatomy.
The Hospital Universitaria 12 Octubre group in Madrid
reported on 120 patients (43% MFS, 12% BAV, 76% re-
ceiving a Tirone David-V-Stanford modification V-SARR)
and showed a 5-year survival and freedom from more
than 2þ AR estimate of 97% and 96%, respectively.23
This corroborates our findings and demonstrates the repro-
ducibility of the Tirone David-V-Stanford modification pro-
cedure at other experienced institutions.rdiovascular Surgery c Volume 145, Number 1 121
FIGURE 2. A, Kaplan-Meier survival curve for 233 patients undergoing valve-sparing aortic root replacement. B, Kaplan-Meier survival curve of 233
patients undergoing valve-sparing aortic root replacement compared with general US population matched for age, gender, and race. C, Kaplan-Meier sur-
vival curves comparing tricuspid (TAV) and bicuspid aortic valve (BAV) subsets. D, Kaplan-Meier survival curves comparing patients with confirmed di-
agnosis of Marfan syndrome or other connective tissue disorders (CTDs) compared with remainder of patients. Vertical bars represent  1 standard error.
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DV-SARR for Patients With BAV
Although patients with BAV had significantly longer
cardiopulmonary bypass and aortic crossclamp times and
more commonly required concomitant aortic arch replace-
ment or cusp-free margin repair (Table 2) compared with
the TAV cohort, the clinical outcome in this subset was
not different from that of the TAV subcohort to date.
This underlines that the Tirone David procedure, with
proper patient selection, is an excellent option for patients
with regurgitant BAVs; however, longer follow-up is122 The Journal of Thoracic and Cardiovascular Surgnecessary. These results are consistent with those from
other investigators24; however, the largest experience
with V-SARR for BAV used aortic root remodeling (Ya-
coub), isolated BAV repair without root replacement, or as-
cending aortic replacement alone, but not V-SARR using
the reimplantation technique.25 Because substantial annu-
lar dilatation is a hallmark of BAV and causes AR owing
to inadequate cusp coaptation height, the use of a V-SARR
procedure that does not reduce the aortic annular size is not
prudent. Despite equal durability to date in our experience,ery c January 2013
FIGURE 3. A, Freedom from reoperation on aortic root after valve-sparing aortic root replacement. B, Freedom from reoperation on aortic root comparing
tricuspid (TAV) and bicuspid aortic valve (BAV) subsets. C, Freedom from reoperation on aortic root after valve-sparing aortic root replacement comparing
patients with confirmedMarfan syndrome or another connective tissue disorder (CTD) and remainder of patient cohort. Vertical bars represent 1 standard
error.
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with a BAV will eventually prove to be inferior than that
for patients with a TAV because the bicuspid valves inex-
orably and progressively become more fibrotic andThe Journal of Thoracic and Caeventually stenotic.8 This makes careful patient selection
crucial. We avoid V-SARR in older patients with a BAV
and those with moderately severe fibrosis or calcification
of the valve.rdiovascular Surgery c Volume 145, Number 1 123
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ber of BAV patients (>70%) have aortic arch dilatation (ie,
Stanford-Fazel clusters III and IV BAV-associated aortop-
athy). This is reflected in our V-SARR experience, in which
arch replacement was performed in 76% of the BAV pa-
tients compared with only 10% of the TAV patients. BAV
aortopathy and arch dilatation is addressed more aggres-
sively at Stanford in these young patients (average age, 43
 12 years) undergoing elective procedures than recom-
mended by others.26 Although the natural history of BAV
indicates a relative low risk of reintervention on the arch
in patients after isolated aortic valve replacement,27 most
of these Ontario patients were older. TheMayo Clinic group
has recommended not replacing the transverse aortic arch in
patients with BAV disease,26 but average age was 55.8 
14.9 years, the arch diameter was only 3.4  0.6 cm,
50% had aortic stenosis, 7% had mixed aortic stenosis/
AR, and 89% underwent AVR. In such a patient population,
we also would not replace the arch. These are different phe-
notypes of BAV disease. Although we do not proclaim
‘‘nearly routine’’ replacement of the aortic arch in patients
with BAV, being aware that in most institutions, arch proce-
dures under hypothermic circulatory arrest carries substan-
tial additional morbidity and mortality, it is performed often
at Stanford, without any added risk of death or stroke.
The present series included 63 BAV patients (or 27%). In
contrast, only 4% of the Hannover Tirone David-I series
had a BAV19; thus, comparing outcomes with respect to
valve morphology is difficult. Our cohort contained a fairly
large fraction of patients with El Khoury type II AR (ie,
cusp prolapse). Most BAV patients with AR due to cusp pro-
lapse had an eccentric AR jet visualized on the preoperative
echocardiogram. Hanke and colleagues6 advocated avoid-
ing V-SARR in such patients because of a greater likelihood
of AR recurrence. Our BAV patients with type II AR have
had excellent clinical and echocardiographic results so
far; however, those with 4þAR preoperatively did not do
as well (Figure E3, A and B). The fairly high number of
cusp repair procedures (TAV 37%, BAV 67%) had no de-
monstrable adverse effect on the outcomes in our analysis,
in contrast to what Hanke and colleagues6 observed. How-
ever, we simply shortened the cusp-free margin without re-
sorting to complete cusp plication, which reduces the
available cusp area.
Regarding the distribution of BAV types encountered
compared with the original seminal publication by Sievers
and colleagues,12 the 304 patients reported by Sievers and
colleagues had undergone either valve replacement or pres-
ervation and were subdivided as type 0 (‘‘naturally perfect
BAV’’) in 7%, type 1 (1 raphe) in 88%, and type 2
(2 raphes) in 5%. In our V-SARR series, the distribution
was type 0 in 30%, type 1 in 70%, and type 2 in none.
This dramatic difference is explained by the far fewer
V-SARR procedures in the experience reported by Sievers124 The Journal of Thoracic and Cardiovascular Surgand colleagues,12 in which reimplantation or remodeling
V-SARR was used in only 1.6% and 1% of patients,
respectively.
V-SARR in Setting of CTD
Patel and colleagues28 reported good early results after
V-SARR in 31 patients with Loeys-Dietz syndrome. We
only had 8 patients with Loeys-Dietz syndrome, and all
did well, except for 1 patient, who later sustained an acute
type B dissection. Because many patients with CTD are ac-
tively lobbying for a V-SARR procedure, a randomization
trial between V-SARR and CVG would be unrealistic.
The safety and long-term durability of the CVG procedure
in patients with MFS has been well documented. In the
worldwide series of 675 patients with MFS compiled by
Gott and colleagues9 in 1999, survival was 94%, 91%,
and 59% at 5, 10, and 20 years, respectively (159 and 4 pa-
tients at risk at 10 and 20 years, respectively). Most MFS
patients are young and therefore usually receive a mechani-
cal valve as a part of the CVG (89% in the report by Gott
and colleagues9) owing to the limited durability of biopros-
thetic and homograft valves. Among the patients who re-
ceived a CVG and were discharged alive from hospital,
90% were free of a thromboembolic event at 20 years.9
Three patients in our Tirone David V-SARR series sus-
tained a thromboembolic event (2 transient ischemic attacks
and 1 stroke), and none had a hemorrhagic complication.
In 2009, David and colleagues7 reported on 103 patients
with MFS who underwent either a Yacoub procedure or Tir-
one David reimplantation V-SARR during 18 years. The
overall results were satisfactory but were inferior for those
who had undergone a Yacoub remodeling procedure. It is
important to emphasize that only 29 V-SARR patients re-
mained at risk at 10 years; therefore, we still do not know
with certainty how durable V-SARR for patients with
MFS will be 10 to 20 years later.
All 6 patients in our serieswho sustained a new typeB aor-
tic dissection had a CTD (5MFS; Table E3 and Figure E1, A
andB).Most had been, orwere currently, taking losartan, an-
other angiotensin II receptor blocker or an angiotensin-
converting enzyme inhibitor. Although anecdotal, this has
prompted us to avoid angiotensin II receptor blocker or
angiotensin-converting enzyme inhibitor therapy postopera-
tively in patients with a CTD. David and colleagues7 also
noted thatmost late deathswere related to downstream aortic
dissection-related complications. Furthermore, computa-
tional fluid dynamic studies have suggested that an ascend-
ing aortic graft increases the distal pulse pressure and
might exacerbate systolic hypertension. 29
ATirone David V-SARR procedure is an excellent option
for most patients with aortic root aneurysm if the aortic
valve cusps are structurally normal, even if AR is present
because of sinotubular junction or annular dilatation or
cusp prolapse, because the AR can be corrected by restoringery c January 2013
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without cusp reconstruction). Yacoub remodeling should be
avoided if annular dilatation is present. Structurally abnor-
mal valve cusps, including severe fibrosis, calcification, or
multiple perforations, are contraindications to V-SARR.
The 20-year prognosis of patients undergoing V-SARR
compared with CVG remains unknown, especially in terms
of all valve-related morbidity and mortality. Therefore, pa-
tients who desire V-SARR to avoid anticoagulation must
accept an unknown—but finite—risk of reoperation in their
lifetimes as a trade-off.
Study Limitations
The present investigation was a retrospective analysis, al-
beit the data were collected prospectively. Only 18 patients
remained at risk beyond 10 years (7 with MFS); thus, only
cautious statements about late results can be supported.
Only 14 adverse events occurred, precluding the use of
a hazard model to identify patient- or disease-related vari-
ables or technical factors associated with a greater likeli-
hood of complications. This highlights the need for
rigorous inspection of larger numbers of patients for longer
follow-up periods before we can conclusively learn the ac-
tual long-term durability of Tirone David V-SARR. Clini-
cally important adverse events (eg, stroke, hemorrhagic
events, infection, SVD, reoperation) occurred rarely, which
would make randomized, prospective studies prohibitively
expensive and unrealistic. The present report included
only selected patients undergoing elective, first-time
V-SARR; more studies similar to that by Leshnower and
colleagues30 from Emory are needed to comprehensively
assess the results of V-SARR in acute settings, especially
for patients with acute type A aortic dissection. However,
the Hannover group is urging caution about performing V-
SARR in patients with acute dissection because of the
greater mortality.19
AR generally is well tolerated; therefore, it is essential to
report the severity of echocardiographic residual/recurrent
AR over time in all surviving patients and not just rely on
the need for reoperation. Because different groups have
used different AR grading systems, and some have reported
only severe AR postoperatively, meaningful comparisons
between reports are difficult. One surgeon (D.C.M.) oper-
ated on nearly all these Stanford patients, making general-
ization of the results to other surgeons or institutions
speculative. Finally, patient-referral and patient-selection
biases were likely present.
CONCLUSIONS
Tirone David reimplantation V-SARR was associated
with excellent clinical and functional outcomes out to 5 to
10 years in patients with and without associated CTDs (pri-
marily MFS) or with a BAV. The incidence of more than 2þ
AR or reoperation at 10 years was very low. AdditionalThe Journal of Thoracic and Cafollow-up is required, however, to characterize the risks,
hazards, and outcomes of V-SARR beyond 10 years.
We thank Stanford Professor Mark Hlatky, MD, for providing
comparative US survival data. We also appreciate and acknowl-
edge the efforts of Michael Sheehan, MSN, RNFA, NPc, in follow-
ing up patients and capturing late echocardiograms.
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Dr Allan S. Stewart (New York, NY). Thanks for the privilege
of discussing this study. It really is a fantastic study with great
early results. Your team should be proud of having an under 1%
operative mortality for a complex operation.
It is a timely question, because right or wrong, we are changing
the paradigm for howwe are dealing with aortic valve disease. Sur-
geons are now implanting biological valves in younger and youn-
ger people, believing the propaganda from our device companies
that the new valves are going to last 20, 25 years, and by that point
in timewewill have worked out the valve-in-valve issue. So in that
30-year-old patient, we are suggesting that there might be just 1 bi-
ological replacement followed by 1 or 2 valve-in-valves. Essen-
tially, we are currently treating patients to prepare for
a technology that is so far unapproved.
So, with that in mind, I have a few questions. The first of which
is age. Your average age was low, around 40 years old, but you do
have 1 or 2 patients whowere older than 60. You are advocating for
valve-sparing operations with few data to support a 20-year
follow-up.
What do you tell your patients as far as the perceived longevity
of a trileaflet or a bicuspid valve?
Dr Kvitting. Thank you very much, Dr Stewart, for your very
insightful comments and questions. I should be careful to make
comments on behalf of Dr Miller in this forum. But, in general,
if the valve is repairable, it should be saved. If there are intraoper-
ative findings that the valve and cusps are not suitable for repair,
the valve should be excised, and the patient should receive a pros-
thetic valve. In older patients with a bicuspid aortic valve, because
they will eventually become stenotic sooner than in young pa-
tients, there are other options that could be better than valve-spar-
ing aortic root replacement; for example, a composite valve graft
with a bioprosthesis or a Freestyle root replacement, which prob-
ably would give the patients a more durable result.126 The Journal of Thoracic and Cardiovascular SurgDr Stewart. The second question I had is on bicuspid valves. It
is a struggle now when we think about bicuspid valves in the set-
ting of perhaps transcatheter valve rescue, because at the end of the
day, it is still a bicuspid valve. It still has the same altered geometry
of the annulus after a valve-sparing procedure; we are still plicat-
ing that conjoined leaflet and creating a more pronounced raphe.
So when that valve fails in the future, might we be doing a disser-
vice to our patients, because in its current iteration, our transcath-
eter solutions do not provide us a rescue for bicuspid valves,
whether it is a native bicuspid or a valve-sparing bicuspid repair.
Dr Kvitting. That is a very good comment. If the transcatheter
aortic valve replacement method holds its promise, it might be that
these patients are better off if they receive a composite graft with,
for example, a 3F equine valve or another bioprosthesis that later
will be more suitable for a valve-in-valve transcatheter aortic valve
replacement procedure. But I still think that it is uncertain whether
that leap of judgment will hold.
Dr Stewart. The next question is, when looking at your data,
you had 3 early failures, all of which had severe preoperative aortic
insufficiency (AI). You only treated 28 patients who started off
with severe AI, so that is a little greater than a 10% early failure
rate in those with severe AI. The 2 questions I have on that are,
1, in the practice of your group, have you altered how you repair
severe AI or perhaps abandoned doing severe AI? The third part
of it is, philosophically, in those young patients who have 4.7-,
4.8-cm aortas, 2 to 3+ AI, you know they are going to require an
operation at some point. Should we be advocating an earlier fix?
I bring this up because when you have severe AI for a while,
you are creating a lot of pressure down on the free edge of those
cusps and destroying it, and perhaps that is a risk factor for early
failure in a valve-sparing operation.
DrKvitting.Another good point. Three patients had severe aor-
tic regurgitation at the initial surgery and sustained structural valve
deterioration; 1 was a bicuspid valve with ruptured commissural
suspensory chords that was fixed by resuspending the cusp with
Gore-Tex suture neochords, which also was done in 2 other pa-
tients. Since that early failure, Dr Miller has abandoned this ap-
proach to correct ruptured suspensory chords with Gore-Tex
sutures. The 2 other patients were both very young and hadMarfan
syndrome; both developed dilatation of their left ventricular out-
flow tract as the mechanism responsible for their recurrent aortic
regurgitation. One of them, an 11-year-old patient, underwent
valve-sparing aortic root replacement and complicated triple ori-
fice mitral valve repair with 2 Alfieri stitches that perhaps, in hind-
sight, should not have been repaired.
Dr Stewart. The last comment is on your 2 most frequent com-
plications. One was the need in 8 patients for a right coronary ar-
tery interposition graft, which seems fairly high. The reason cited
was technical complications. However, that was 8 of 230. It seems
like a lot of right coronary injuries requiring a graft. I was wonder-
ing what you do to correct that.
Also, then, your patients withMarfan syndrome; 6 with a type B
dissection. I know that your group uses a pretty aggressive penin-
sula repair technique for the arch. I was unable to ferret out in your
Marfan group if they had received that technique and perhaps that
was predisposing them to a flow change in the distal arch and per-
haps that was not predisposing them to a dissection. Do you have
any comments on that?ery c January 2013
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patients had undergone arch repair because they did not have bi-
cuspid valves. We know from others, for example, Professor Da-
vid’s data from Toronto, that downstream complications,
including the development of type B dissections, is known to occur
in patients with Marfan syndrome, which mandates assiduous sur-
veillance and careful b-blocker therapy with or without losartan.
We do not believe these dissections were related directly or indi-
rectly to our initial valve-preserving root replacement. Finally, re-
garding whether there was a high number of right coronary artery
injuries requiring an interposition graft, I cannot personally com-
ment on that. Sorry, sir.
Dr Smith. Dr Miller, did you want to answer that?
Dr D. Craig Miller (Stanford, Calif). Thank you, Craig. Being
responsible for most of them, indeed, I can comment. Most of these
patients had bicuspid valves and nondominant, small right coronary
arteries that fell apart during reimplantation with a Carrel patch. As
Tirone David andNickKouchoukos have shown,many early deaths
after aRoss procedure result from troublewith a small, nondominant
right coronary artery. Our solution for decades has been to do a very
short (2-3 cm) interposition graft using the large saphenous vein har-
vested from the thigh, termed a ‘‘Kay-Zubiate’’. JeromeKay andPa-
blo Zubiate in the late 1970s described how one can bail out of
trouble with this little vein graft. Interestingly, I just saw this very
old technique repopularized in a recent report with no reference
whatsoever to the original publication from decades ago. But, it
was due to technical problems, Allan; whether our rate was too
high, I do not know, but I do take responsibility for these problems.
Dr Christian Etz (Leipzig, Germany).On the same topic on the
bicuspids, you did not observe any difference in overall survival
among the 3 groups, obviously reflecting not only excellent patient
selection. We just presented our experience from Leipzig of a co-
hort of 476 patients of more than 1200 patients who underwent
root replacement, all with the samemechanical composite prosthe-
sis, at the Aortic Symposium in New York last week, and we found
similar results as you just presented, with an overall longevity
equivalent to an age- and gender-matched population after the first
postoperative year.
A subgroup analysis, however, in our bicuspid patients revealed
a significantly better long-term outcome; they were basically
cured, but those with tricuspid valves had significantly worse lon-
gevity after discharge, clearly inferior to that of their age- and gen-
der-matched normal population.
We also found, surprisingly, significantly worse longevity in
women, a finding that we had previously seen among patients re-
ceiving biological conduits in our Sinai series. So I was wondering
whether you had analyzed gender differences and could you com-
ment on your understanding as to what might protect bicuspid pa-
tients down the road?
Dr Kvitting. We have to go back and study whether gender
influenced the outcomes in our cohort. I saw your presentation
in New York. I am wondering a little bit whether perhaps your
data were biased because many of the tricuspid valves were prob-
ably associated with having some sort of connective tissue disorder
in a greater proportion than in patients with a bicuspid aortic valve
and that might be why having a bicuspid valve was protective, be-
cause they have less extensive aortic disease than the tricuspid
population. But that is just guessing from my side.The Journal of Thoracic and CaDr Etz. They were actually excluded. But perhaps it was be-
cause it is a mark of atherosclerosis. That was our understanding.
Also, our tricuspid valve population was significantly older than
yours, even older than those with bicuspid valves. So that also
might have shifted this a little bit.
Dr Oz Shapira (Jerusalem, Israel). Thank you for an excellent
presentation. My question is regarding the basic comparison
groups. Given that you had a large proportion of patients withMar-
fan syndrome in the tricuspid aortic valve group and a separate bi-
cuspid valve group, and given the large body of evidence
suggesting that a bicuspid aortic valve is associated with connec-
tive tissue disease of the aorta itself, would it have been more log-
ical to include the patients with Marfan syndrome and bicuspid
aortic valve in 1 group and compare them with the patients with
tricuspid aortic valves without Marfan syndrome? The long-term
adverse outcomes in the present study were mostly affected by
the presence of connective tissue disorder. Restructuring the study
groups might make a large difference in interpreting the results.
Thank you.
Dr Kvitting. That is a very good and valid point. We just dis-
cussed that point a few days ago, that perhaps we are giving the pa-
tients with tricuspid valves more than just 1 disease because they
are associated with a greater number of concomitant connective
tissue disorders. But it might be valuable to just try to do that
and group the valves together to determine whether valves with
or without associated aortic disease have a different outcome.
Dr Tirone E. David (Toronto, Ontario, Canada). This is more
a comment than a question. I think it is wonderful that you are doing
this operation and trying to determine its limitations. Whoever read
myveryfirst paper or heardmepresenting during thefirst decade, the
sentence I used was ‘‘normal’’ aortic cusps. During the first decade
of our experience, we never tried to do valve-sparing reimplantation
or remodeling in patients who had abnormal cusps. As experience
increased, we decided to treat patients with a bicuspid aortic valve
and prolapsing or defective cusps with large fenestrations.
Last week in New York City I presented Dr Feindel’s and my
experience with 296 reimplantations only. The longest follow-up
was 22 years. Unfortunately, only 21 patients were at risk at 15
years. Approximately one third had Marfan syndrome. Only 32
had bicuspid aortic valves. Only 11 patients developed moderate
or severe aortic insufficiency, one third of them in bicuspid aortic
valve group and none in the Marfan syndrome. Actually, on mul-
tivariate analysis, Marfan syndromewas the only independent pre-
dictor of AI on the beneficial side, that is, the hazard ratio was less
than 1. In other words, in our hands, Marfan syndrome was protec-
tive, not detrimental, to good outcomes.
Bicuspid aortic valve on univariate analysis was predictor of
failure but not on multivariate analysis. Again, our sample size
was too small.
Theanatomyof the bicuspidvalve ishighlyvariable.Type0 isper-
fect for valve sparing. If you have type 1 or 2 and the further away the
cusps are, the more difficult to perform a reimplantation into a cylin-
der or a Valsalva graft or the way you do the reimplantation.
I think we should be a bit more cautious with the reimplantation
technique in bicuspid aortic valve. Actually, in any reimplantation,
the cusps must be relatively normal for us to embark on this diffi-
cult operation.
Thank you.rdiovascular Surgery c Volume 145, Number 1 127
FIGURE E1. A, Freedom from Stanford type B aortic dissection for all patients. B, Freedom from Stanford type B aortic dissection comparing patients
with confirmed diagnosis of Marfan syndrome or other connective tissue disorder (CTD) with remainder of patients. C, Freedom from more than 2þaortic
regurgitation. Vertical bars represent  1 standard error.
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FIGUREE2. A, Freedom from structural valve deterioration (SVD) after valve-sparing aortic root replacement. B, Freedom fromSVD comparing tricuspid
(TAV) and bicuspid aortic valve (BAV) subsets. C, Freedom from SVD comparing patients with confirmed diagnosis of Marfan syndrome or other connective
tissue disorder (CTD) and remainder of patients. Vertical bars represent  1 standard error.
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FIGUREE3. A, Freedom from structural valve deterioration comparing patients with 4þaortic regurgitation (AR) preoperatively and remainder of patients.
B, Freedom from reoperation on aortic root comparing patients with 4þaortic regurgitation preoperatively and remainder of patients. Vertical bars represent
 1 standard error.
TABLE E1. Early postoperative complications among 233 Tirone
David valve-sparing aortic root replacement patients
Variable Value
In-hospital mortality (30 d) 2 (0.9)
Mediastinal re-exploration because of bleeding 8 (3)
Cardiac complications
Acute myocardial infarction 1 (0.4)
Atrial fibrillation 29 (12)
Permanent pacemaker 8 (3)
Stroke 2 (0.9)
Acute renal dysfunction 0
Length of hospital stay (d)
Median 6
IQR 5-7
Data presented as n (%) or median and IQR. IQR, Interquartile range.
TABLE E2. Complications in 231 surviving Tirone David valve-
sparing aortic root replacement patients
Variable n (%)
Superficial wound infection 2 (0.9)
Deep sternal infection 1 (0.4)
Late mortality 2 (0.9)
Thromboembolism 3 (1.3)
TIA 2 (0.9)
Stroke 1 (0.4)
Bleeding events 0
Endocarditis requiring operative management 2 (0.9)
Acute type B aortic dissection 6 (2.6)
Conservative therapy 6 (2.6)
Operative treatment 0
Reoperation for structural valve deterioration 3 (1.3)
AVR 3 (1.3)
Repeat repair 0
Late pacemaker 3 (1.3)
Third-degree AV block 3 (1.3)
AV, Atrioventricular; AVR, aortic valve replacement; TIA, transient ischemic attack.
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TABLE E3. Clinical characteristics of 6 patients with Stanford type B dissection
Variable
Pt. no.
1 2 3 4 5 6
Age at operation (y) 48 32 32 36 19 26
Gender F M F F F F
CTD MFS MFS MFS MFS MFS LDS
Operation type TD-I TD-V TD-V-S-Mod TD-V-S-Mod TD-V-S-Mod TD-V-S-Mod
Graft diameter (cm) 26 32 34 30 30 30
Proximal or annular end 26 27 25 25 27 25
Distal 26 32 20 22 20 20
Aortic valve type TAV TAV TAV BAV TAV TAV
Preoperative AR þ3 0 þ3 0 þ3 0
Postoperative AR þ1 þ1 þ1 þ1 þ1 0
Interval to dissection (mo) 103 100 34 42 19 23
AR, Aortic regurgitation; BAV, bicuspid aortic valve; CTD, connective tissue disorder; F, female; LDS, Loeys-Dietz syndrome;M,male;MFS,Marfan syndrome; Pt. no., patient
number; TAV, tricuspid aortic valve; TD-I, Tirone David-I valve-sparing aortic root replacement; TD-V, Tirone David-V valve-sparing aortic root replacement; TD-V-S-Mod, Tir-
one David-V-Stanford modification valve-sparing aortic root replacement.
TABLE E4. Clinical characteristics of 4 patients with structural valve deterioration after Tirone David valve-sparing aortic root replacement
Variable
Pt. no.
1 2 3 4
Age at operation (y) 44 18 27 11
Gender Female Male Male Male
CTD None MFS None MFS
Preoperative AR None Severe Severe Severe
V-SARR procedure type TD-I TD-V-S-Mod TD-V-S-Mod TD-V-S-Mod
Aortic valve type TAV TAV BAV, 1/L-R/r TAV
Valve repair No No Yes; Gore-Tex neochord Yes; cusp FM shortening
Postoperative AR None Mild Mild None
AR before reoperation Severe Severe Severe Severe
Interval to reoperation (mo) 77 55 33 NA*
AR, Aortic regurgitation; BAV, bicuspid aortic valve; CTD, connective tissue disorder; FM, free margin; MFS, Marfan syndrome; Pt. no., patient number; TAV, tricuspid aortic
valve; TD-I, Tirone David-I valve-sparing aortic root replacement; TD-V-S-Mod, Tirone David-V-Stanford modification valve-sparing aortic root replacement. *Patient 4 under-
went aortic valve replacement after end of the study closing interval and 53 months after valve-sparing aortic root replacement and mitral valve repair.
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TABLE E5. Overview of variables tested in Cox proportional hazard
regression analysis (n ¼ 233)
Variable HR 95% CI P value
Age (y) 0.902 0.845-0.962 .002
Gender 1.963 0.393-9.794 .411
Weight (kg) 1.015 0.967-1.066 .550
Height (m) 0.944 0.887-1.005 .073
STBSA (m2) 0.818 0.0216-30.903 .915
LVEF (%) 0.953 0.871-1.042 .289
MFS or other CTD 3.506 0.567-21.675 .177
BAV 6.426 0.747-55.318 .090
Aortic cusp repair 0.686 0.166-2.832 .603
Arch replacement 12.377 1.289-118.879 .029
CPB time (min) 1.000 0.984-1.016 .994
Crossclamp time (min) 1.002 0.978-1.027 .879
AR>2þpreoperative 6.038 1.361-26.795 .018
For this analysis, we constructed a composite endpoint, but only 14 total adverse
events occurred (4 deaths [2 in-hospital and 2 late], 4 SVD, 3 reoperations [not due
to SVD, 2 caused by endocarditis], 1 stroke, and 2 TIA); small number of events
made Cox model unstable, providing unreliable results without clinical relevance,
as shown by extremely wide 95% confidence intervals. AR, Aortic regurgitation;
BAV, bicuspid aortic valve; CI, confidence interval; CPB, cardiopulmonary bypass;
CTD, connective tissue disorder; HR, hazard ratio; LVEF, left ventricular ejection
fraction; MFS, Marfan syndrome.
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